These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12851604)

  • 1. One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction.
    Sinnaeve P; Alexander J; Belmans A; Bogaerts K; Langer A; Diaz R; Ardissino D; Vahanian A; Pehrsson K; Armstrong P; Van de Werf F;
    Am Heart J; 2003 Jul; 146(1):27-32. PubMed ID: 12851604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.
    ; Van De Werf F; Adgey J; Ardissino D; Armstrong PW; Aylward P; Barbash G; Betriu A; Binbrek AS; Califf R; Diaz R; Fanebust R; Fox K; Granger C; Heikkilä J; Husted S; Jansky P; Langer A; Lupi E; Maseri A; Meyer J; Mlczoch J; Mocceti D; Myburgh D; Oto A; Paolasso E; Pehrsson K; Seabra-Gomes R; Soares-Piegas L; Sùgrue D; Tendera M; Topol E; Toutouzas P; Vahanian A; Verheugt F; Wallentin L; White H
    Lancet; 1999 Aug; 354(9180):716-22. PubMed ID: 10475182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.
    Dunn CJ; Goa KL
    Am J Cardiovasc Drugs; 2001; 1(1):51-66. PubMed ID: 14728052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes.
    Mehta RH; Alexander JH; Van de Werf F; Armstrong PW; Pieper KS; Garg J; Califf RM; Granger CB
    JAMA; 2005 Apr; 293(14):1746-50. PubMed ID: 15827313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
    Sinnaeve PR; Alexander JH; Bogaerts K; Belmans A; Wallentin L; Armstrong P; Adgey JA; Tendera M; Diaz R; Soares-Piegas L; Vahanian A; Granger CB; Van De Werf FJ
    Am Heart J; 2004 Jun; 147(6):993-8. PubMed ID: 15199346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction.
    InTIME-II Investigators
    Eur Heart J; 2000 Dec; 21(24):2005-13. PubMed ID: 11102251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3).
    Curtis JP; Alexander JH; Huang Y; Wallentin L; Verheugt FW; Armstrong PW; Krumholz HM; Van de Werf F; Danays T; Cheeks M; Granger CB;
    Am J Cardiol; 2004 Aug; 94(3):279-83. PubMed ID: 15276088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenecteplase: new preparation. Another thrombolytic agent for myocardial infarction: a slightly simpler treatment.
    Prescrire Int; 2002 Jun; 11(59):83-4. PubMed ID: 12068843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.
    Tanswell P; Modi N; Combs D; Danays T
    Clin Pharmacokinet; 2002; 41(15):1229-45. PubMed ID: 12452736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction.
    Al-Shwafi KA; de Meester A; Pirenne B; Col JJ
    Am Heart J; 2003 Feb; 145(2):217-25. PubMed ID: 12595837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenecteplase for treatment of acute myocardial infarction.
    Turcasso NM; Nappi JM
    Ann Pharmacother; 2001 Oct; 35(10):1233-40. PubMed ID: 11675853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction.
    Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators
    N Engl J Med; 1997 Oct; 337(16):1124-30. PubMed ID: 9340504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review.
    Dundar Y; Hill R; Dickson R; Walley T
    QJM; 2003 Feb; 96(2):103-13. PubMed ID: 12589008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2.
    Gupta M; Chang WC; Van de Werf F; Granger CB; Midodzi W; Barbash G; Pehrson K; Oto A; Toutouzas P; Jansky P; Armstrong PW;
    Eur Heart J; 2003 Sep; 24(18):1640-50. PubMed ID: 14499226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-month survival in 20,891 patients with acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. GISSI-2 and International Study Group. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto.
    Eur Heart J; 1992 Dec; 13(12):1692-7. PubMed ID: 1289101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-target effects of thrombolytic drugs: apolipoprotein A-I proteolysis by alteplase and tenecteplase.
    Gomaraschi M; Ossoli A; Vitali C; Pozzi S; Vitali Serdoz L; Pitzorno C; Sinagra G; Franceschini G; Calabresi L
    Biochem Pharmacol; 2013 Feb; 85(4):525-30. PubMed ID: 23219857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.
    Van de Werf F; Cannon CP; Luyten A; Houbracken K; McCabe CH; Berioli S; Bluhmki E; Sarelin H; Wang-Clow F; Fox NL; Braunwald E
    Am Heart J; 1999 May; 137(5):786-91. PubMed ID: 10220625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
    Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
    Lancet; 2001 Aug; 358(9282):605-13. PubMed ID: 11530146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings.
    Sarullo FM; Pasquale PD; D'Alfonso G; Amerigo L; Cannizzaro S; Castello A
    Ital Heart J; 2001 Aug; 2(8):605-11. PubMed ID: 11577835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.